Alpha Cognition (ACOG) announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of Zunveyl in the long-term care setting.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACOG: